These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34204910)

  • 1. The Usefulness of a Duplex RT-qPCR during the Recent Yellow Fever Brazilian Epidemic: Surveillance of Vaccine Adverse Events, Epizootics and Vectors.
    Queiroz ALN; Barros RS; Silva SP; Rodrigues DSG; Cruz ACR; Dos Santos FB; Vasconcelos PFC; Tesh RB; Nunes BTD; Medeiros DBA
    Pathogens; 2021 Jun; 10(6):. PubMed ID: 34204910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow Fever Vaccine-Associated Viscerotropic Disease among Siblings, São Paulo State, Brazil.
    Fernandes EG; Gomes Porto VB; de Oliveira PMN; Duarte-Neto AN; de Sousa Maia ML; Lignani LK; Nogueira JS; Teixeira GV; Iglezias SD; Blanco RM; Sato HK
    Emerg Infect Dis; 2023 Mar; 29(3):493-500. PubMed ID: 36823036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
    Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
    Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
    Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
    Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination.
    Rezende IM; Alves PA; Arruda MS; Gonçalves AP; Oliveira GFG; Pereira LS; Dutra MRT; Campi-Azevedo AC; Valim V; Tourinho R; Oliveira JG; Calzavara CE; Said RFDC; Kroon EG; Martins-Filho OA; Teixeira-Carvalho A; Drumond BP
    Vaccines (Basel); 2019 Dec; 7(4):. PubMed ID: 31817103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yellow fever epizootics in non-human primates, Southeast and Northeast Brazil (2017 and 2018).
    Mares-Guia MAMM; Horta MA; Romano A; Rodrigues CDS; Mendonça MCL; Dos Santos CC; Torres MC; Araujo ESM; Fabri A; de Souza ER; Ribeiro ROR; Lucena FP; Junior LCA; da Cunha RV; Nogueira RMR; Sequeira PC; de Filippis AMB
    Parasit Vectors; 2020 Feb; 13(1):90. PubMed ID: 32075684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent sylvatic yellow fever virus transmission in Brazil: the news from an old disease.
    Silva NIO; Sacchetto L; de Rezende IM; Trindade GS; LaBeaud AD; de Thoisy B; Drumond BP
    Virol J; 2020 Jan; 17(1):9. PubMed ID: 31973727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches for the standardization and validation of a real-time qPCR assay using TaqMan probes for quantification of yellow fever virus on clinical samples with high quality parameters.
    Fernandes-Monteiro AG; Trindade GF; Yamamura AM; Moreira OC; de Paula VS; Duarte AC; Britto C; Lima SM
    Hum Vaccin Immunother; 2015; 11(7):1865-71. PubMed ID: 26011746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions.
    Fradico JRB; Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JGA; Faria ES; Drumond BP; de Rezende IM; Almeida JF; da Silva RB; Gusmão JD; Arcoverde Medeiros EL; Rodrigues RCM; Ribeiro JGL; Pereira MA; Silva MVF; Rocha MLC; Adelino TER; de Melo Iani FC; Pereira GC; Fernandes EG; Auxiliadora-Martins M; Valim V; de Souza Gomes M; Amaral LR; Romano APM; Ramos DG; Carvalho SMD; Fantinato FFST; do Carmo Said RF; Teixeira-Carvalho A; Martins-Filho OA
    Vaccine; 2021 Jul; 39(31):4359-4372. PubMed ID: 34147295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Curr Drug Saf; 2011 Jul; 6(3):145-54. PubMed ID: 22122389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-type Yellow fever virus in cerebrospinal fluid from fatal cases in Brazil, 2018.
    de Rezende IM; Cenachi ARC; Costa TA; Oliveira GFG; Rabelo L; Menezes LM; Penido I; Pereira LS; Arruda MS; Gonç Alves AP; Alves PA; Kroon EG; Calzavara-Silva CE; Ramalho DB; Martins-Filho OA; Teixeira-Carvalho A; LaBeaud AD; Drumond BP
    Front Virol; 2022; 2():. PubMed ID: 37461745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yellow fever virus investigation in tissues of vampire bats Desmodus rotundus during a wild yellow fever outbreak in Brazilian Atlantic Forest.
    Cupertino MDC; Bayão TS; Xisto MF; Paula SO; Ribeiro SP; Montenegro SSP; Freitas MB; Gomes AP; Siqueira-Batista R
    Comp Immunol Microbiol Infect Dis; 2022 Oct; 89():101869. PubMed ID: 36115128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sero-prevalence of yellow fever and related Flavi viruses in Ethiopia: a public health perspective.
    Mengesha Tsegaye M; Beyene B; Ayele W; Abebe A; Tareke I; Sall A; Yactayo S; Shibeshi ME; Staples E; Belay D; Lilay A; Alemu A; Alemu E; Kume A; H/Mariam A; Ronveaux O; Tefera M; Kassa W; Bekele Weyessa A; Jima D; Kebede A; Tayachew A
    BMC Public Health; 2018 Aug; 18(1):1011. PubMed ID: 30107830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
    Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of Yellow fever virus outside the Amazon Basin, causing epidemics in Southeast Brazil, from 2016 to 2018.
    Rezende IM; Sacchetto L; Munhoz de Mello É; Alves PA; Iani FCM; Adelino TÉR; Duarte MM; Cury ALF; Bernardes AFL; Santos TA; Pereira LS; Dutra MRT; Ramalho DB; de Thoisy B; Kroon EG; Trindade GS; Drumond BP
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006538. PubMed ID: 29864115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mouse model for studying viscerotropic disease caused by yellow fever virus infection.
    Meier KC; Gardner CL; Khoretonenko MV; Klimstra WB; Ryman KD
    PLoS Pathog; 2009 Oct; 5(10):e1000614. PubMed ID: 19816561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.